Joachim Janda

Dr. Joachim Janda

Metabolic Center, University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Water Research
Verified
Journal Article
Closed access
MSMarco Scheurer
Marco Scheurer
KNKarsten Nödler
Karsten Nödler
FFFinnian Freeling
Finnian Freeling
Joachim JandaJoachim Janda
Joachim Janda
OHOliver Happel
Oliver Happel
HBHeinz-Jürgen Brauch
Heinz-Jürgen Brauch

19 March 2018 in Environmental Science and Pollution Research
Verified
Journal Article
Closed access
PDF file
Joachim JandaJoachim Janda
Joachim Janda
KNKarsten Nödler
Karsten Nödler
HBHeinz-Jürgen Brauch
Heinz-Jürgen Brauch
CZChristian Zwiener
Christian Zwiener
FLFrank T. Lange
Frank T. Lange

30 May 2019 in Environmental Science: Processes & Impacts
Verified
Journal Article
Closed access
PDF file
Joachim JandaJoachim Janda
Joachim Janda
KNKarsten Nödler
Karsten Nödler
MSMarco Scheurer
Marco Scheurer
OHOliver Happel
Oliver Happel
GNGudrun Nürenberg
Gudrun Nürenberg
FLFrank Thomas Lange
Frank Thomas Lange
An improved protocol of the total oxidizable precursor (TOP) assay was developed for precursors to C2–C14 perfluoroalkyl carboxylic acids (PFCAs) and C4–C8 and C10 perfluoroalkyl sulfonic acids (PFSAs). The proposed protocol was tested and validated for contaminated soil samples. The perfluoroalkyl acids (PFAAs) present in the soil extract solutions after oxidation with persulfate were separated from the inorganic salts by vacuum-assisted drying of the digestion solution followed by solid–liquid extraction of the PFAAs with acetonitrile from the dry residue. Ion chromatography (for C2–C4 PFCAs) and reversed phase liquid chromatography (for all other PFASs), both coupled to tandem mass spectrometry, were used for quantification. High procedural recoveries of PFAAs between 68% and 123% with RSDs between 0.2% and 25% (n = 3) were achieved. The method was validated using selected polyfluoroalkyl phosphoric acid esters (PAPs) and bis-[2-(N-ethyl perfluorooctane-1-sulfonamido)ethyl] phosphoric acid ester (diSAmPAP) as model precursors in pure solutions and in the presence of soil matrix. The oxidation led to characteristic and reproducible PFCA patterns (in the case of PAPs) or PFOA (in the case of diSAmPAP) with total reaction yields between 92 ± 4% and 123 ± 13% (n = 3). The impact of the soil matrix on transformation yields was negligible. In a soil core from a PFAS-polluted agricultural site, precursors were concentrated in the upper 40 cm with long-chain precursors being prevalent. After oxidative digestion, the total molar PFAA-concentrations increased by factors of 1.6 to 5.0. More than 40 cm below ground precursors of TFAA, PFPrA and PFBA accounted for ∼50% of the reaction products, underlining the importance of their inclusion in mass balances based on the TOP assay.

10 March 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RTRafael Tesorero
Rafael Tesorero
Joachim JandaJoachim Janda
Joachim Janda
FHFriederike Hörster
Friederike Hörster
PFPatrik Feyh
Patrik Feyh
UMUlrike Mütze
Ulrike Mütze
JOJürgen G Okun
Jürgen G Okun
Early diagnosis of severe combined immunodeficiency (SCID), spinal muscular atrophy (SMA), and sickle cell disease (SCD) improves health outcomes by providing a specific treatment before the onset of symptoms. A high-throughput nucleic acid-based method in newborn screening (NBS) has been shown to be fast and cost-effective in the early detection of these diseases. Screening for SCD has been included in Germany’s NBS Program since Fall 2021 and typically requires high-throughput NBS laboratories to adopt analytical platforms that are demanding in terms of instrumentation and personnel. Thus, we developed a combined approach applying a multiplexed quantitative real-time PCR (qPCR) assay for simultaneous SCID, SMA, and 1st-tier SCD screening, followed by a tandem mass spectrometry (MS/MS) assay for 2nd-tier SCD screening. DNA is extracted from a 3.2-mm dried blood spot from which we simultaneously quantify T-cell receptor excision circles for SCID screening, identify the homozygous SMN1 exon 7 deletion for SMA screening, and determine the integrity of the DNA extraction through the quantification of a housekeeping gene. In our two-tier SCD screening strategy, our multiplex qPCR identifies samples carrying the HBB: c.20A>T allele that is coding for sickle cell hemoglobin (HbS). Subsequently, the 2nd tier MS/MS assay is used to distinguish heterozygous HbS/A carriers from samples of patients with homozygous or compound heterozygous SCD. Between July 2021 and March 2022, 96,015 samples were screened by applying the newly implemented assay. The screening revealed two positive SCID cases, while 14 newborns with SMA were detected. Concurrently, the qPCR assay registered HbS in 431 samples which were submitted to 2nd-tier SCD screening, resulting in 17 HbS/S, five HbS/C, and two HbS/β thalassemia patients. The results of our quadruplex qPCR assay demonstrate a cost-effective and fast approach for a combined screening of three diseases that benefit from nucleic-acid based methods in high-throughput NBS laboratories.

3 October 2022 in Clinical Biochemistry
Verified
Journal Article
Closed access
PMPéter Monostori
Péter Monostori
MGMarkus Godejohann
Markus Godejohann
Joachim JandaJoachim Janda
Joachim Janda
ZGZsolt Galla
Zsolt Galla
GRGábor Rácz
Gábor Rácz
JOJürgen G. Okun
Jürgen G. Okun

25 September 2023 in Klinische Padiatrie
Verified
Journal Article
Open access
PDF file
Joachim JandaJoachim Janda
Joachim Janda
SHSebastian Hegert
Sebastian Hegert
JBJessica Bzdok
Jessica Bzdok
RTRafael Tesorero
Rafael Tesorero
UHUte Holtkamp
Ute Holtkamp
JDJürgen Durner
Jürgen Durner
Background Sickle cell disease (SCD) is a group of hemoglobinopathies with a common point mutation causing the production of sickle cell hemoglobin (HbS). In high-throughput newborn screening (NBS) for SCD, a two-step procedure is suitable, in which qPCR first pre-selects relevant samples that are differentiated by a second method. Methods Three NBS centers using qPCR-based primary screening for SCD performed a laboratory comparison. Methods using tandem MS or HPLC were used for differentiation. Results In a benchmarking test, 450 dried blood samples were analyzed. Samples containing HbS were detected as reliably by qPCR as by methods established for hemoglobinopathy testing. In a two-step screening approach, the 2nd-tier-analyses have to distinguish the carrier status from pathological variants. In nine months of regular screening, a total of 353,219 samples were analyzed using two-stage NBS procedures. The 1st-tier screening by qPCR reduced the number of samples for subsequent differentiation by>99.5%. Cases with carrier status or other variants were identified as inconspicuous while 78 cases with SCD were revealed. The derived incidence of 1:4,773, is in good agreement with previously published incidences. Conclusion In high-throughput NBS for SCD, qPCR is suitable to focus 2nd-tier analyses on samples containing HbS, while being unaffected by factors such as prematurity or transfusions. The substantial reduction of samples numbers positively impacts resource conservation, sustainability, and cost-effectiveness. No false negative cases came to attention. Hintergrund Die Sichelzellkrankheit (SCD) bezeichnet eine Gruppe von Hämoglobinopathien mit einer gemeinsamen Punktmutation, die zur Bildung von Sichelzell-Hämoglobin (HbS) führt. Für das Hochdurchsatz-Neugeborenenscreening (NGS) auf SCD bietet sich ein zweistufiges Verfahren an, in dem die qPCR HbS-haltige Proben vorselektiert, die mit einer zweiten Methode differenziert werden. Methoden Drei NGS-Zentren, in denen ein qPCR-basiertes Primärscreening auf SCD durchgeführt wird, haben sich einem Laborvergleich unterzogen. Zur Differenzierung wurden Tandem-MS oder HPLC genutzt. Ergebnisse In einem Laborvergleich mit 450 Trockenblutproben wurden HbS-haltige Proben mit qPCR ebenso zuverlässig erkannt, wie mit Methoden die zur Untersuchung von Hämoglobinopathien etabliert sind. Der Fokus der Folgeanalytik liegt beim zweistufigen SCD Screening somit auf der Unterscheidung zwischen Trägerstatus und pathologischen Varianten. In neun Monaten Regelscreening wurden insgesamt 353.219 Proben untersucht, wobei das 1st-tier-NGS mittels qPCR die Probenzahl für die Differenzierung um>99,5% reduzierte. Fälle mit Trägerstatus oder andere Varianten wurden als unauffällig erkannt und 78 Fälle mit SCD diagnostiziert. Die abgeleitete Inzidenz von 1:4.773, stimmt gut mit bislang publizierten Inzidenzen überein. Schlussfolgerung Im Hochdurchsatz-NGS auf SCD ist qPCR geeignet, um die Folgeanalytik auf Proben zu fokussieren, die HbS enthalten und dabei von Störkonstellationen wie Frühgeburtlichkeit oder Transfusionen unbeeinflusst zu sein. Die erhebliche Reduzierung der Probenzahl wirkt sich positiv auf Ressourcenschonung, Nachhaltigkeit und Wirtschaftlichkeit aus. Falsch negative Befunde sind nicht bekannt geworden. Article published online: 25 September 2023 © 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany